38 results match your criteria: "Lyme Disease Research Center[Affiliation]"

Lyme disease, the most widespread tick-borne disease in North America, is caused by the bacterium Borrelia burgdorferi (Bb). Approximately 10-15% of infections result in neuroborreliosis, common symptoms of which include headaches, facial palsy, and long-term cognitive impairment. Previous studies of Bb dissemination focus on assessing Bb transmigration at static time points rather than analyzing the complex dynamic process of extravasation.

View Article and Find Full Text PDF

Background: Research on patients with persistent symptoms despite prior treatment for Lyme disease can be challenging to interpret given the diversity of criteria selected to characterize Lyme disease and to define the syndrome of those with persistent symptoms. Because most research studies only include patients with well-documented prior Lyme disease, the generalizability of the study results is limited, excluding the larger group of patients often seen in community practice who do not meet these stringent enrollment criteria. Researchers at the Lyme and other Tick-borne Diseases Clinical Trials Network (LTD-CTN) recognized early on that a research classification system was needed to facilitate the design of studies that are more inclusive.

View Article and Find Full Text PDF

A comparison of genome-wide association analyses of persistent symptoms after Lyme disease, fibromyalgia, and myalgic encephalomyelitis - chronic fatigue syndrome.

BMC Infect Dis

February 2025

Department of Population Health Sciences, Geisinger Health System, 100 N. Academy Avenue, Danville, PA, 17822-4400, United States of America.

Background: Up to 20% of Lyme disease cases experience post-treatment Lyme disease syndrome (PTLDS). The biological basis for PTLDS is poorly understood and no evidence-based treatment has been identified. Genetic studies have the potential to elucidate PTLDS pathophysiology and identify treatment targets.

View Article and Find Full Text PDF

Background: The geographic footprint of Lyme disease is expanding in the United States, which calls for novel methods to identify emerging endemic areas. The ubiquity of internet use coupled with the dominance of Google's search engine makes Google user search data a compelling data source for epidemiological research.

Objective: We evaluated the potential of Google Health Trends to track spatiotemporal patterns in Lyme disease and identify the leading edge of disease risk in the United States.

View Article and Find Full Text PDF

A sex-based analysis of complete blood count features during acute, untreated Lyme disease.

Front Med (Lausanne)

October 2024

Lyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Introduction: Although lymphopenia has been described in acute Lyme disease (LD), the complete blood count (CBC) has not been comprehensively examined, nor have sex-based analyses been conducted. We analyzed CBC values and identified sex-based trends among patients with early LD by comparing both to controls without a history of LD and to patients' pre-morbid values.

Methods: We enrolled participants from the Mid-Atlantic US with diagnostic erythema migrans and controls with no history of LD.

View Article and Find Full Text PDF

Invalidation by medical professionals in post-treatment Lyme disease.

Sci Rep

August 2024

Lyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Patients with post-treatment Lyme disease (PTLD) report negative perceptions of care and significant invalidation from medical professionals. However, the relationship of invalidation to illness severity has not been examined, nor have risk factors for invalidation been identified. This cross-sectional study enrolled 80 patients who met stringent criteria for PTLD.

View Article and Find Full Text PDF

Outpatient visits before and after Lyme disease diagnosis in a Maryland employer-based health plan.

BMC Health Serv Res

August 2023

Lyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: Insurance claims data have been used to inform an understanding of Lyme disease epidemiology and cost of care, however few such studies have incorporated post-treatment symptoms following diagnosis. Using longitudinal data from a private, employer-based health plan in an endemic US state, we compared outpatient care utilization pre- and post-Lyme disease diagnosis. We hypothesized that utilization would be higher in the post-diagnosis period, and that temporal trends would differ by age and gender.

View Article and Find Full Text PDF

Dendritic cells bridge the innate and adaptive immune responses by serving as sensors of infection and as the primary APCs responsible for the initiation of the T cell response against invading pathogens. The naive T cell activation requires the following three key signals to be delivered from dendritic cells: engagement of the TCR by peptide Ags bound to MHC molecules (signal 1), engagement of costimulatory molecules on both cell types (signal 2), and expression of polarizing cytokines (signal 3). Initial interactions between Borrelia burgdorferi, the causative agent of Lyme disease, and dendritic cells remain largely unexplored.

View Article and Find Full Text PDF

Initial Presentation and Time to Treatment in Early Lyme Disease.

Am J Trop Med Hyg

April 2023

Division of Rheumatology, Department of Medicine, Lyme Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

The erythema migrans (EM) rash is an important initial diagnostic sign of early Lyme disease. We tested the hypothesis that patients who noticed EM first differed from those who noticed viral-like symptoms first. "EM First" participants (167/271, 61.

View Article and Find Full Text PDF

Gene set predictor for post-treatment Lyme disease.

Cell Rep Med

November 2022

Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1603, New York, NY 10029, USA. Electronic address:

Lyme disease (LD) is tick-borne disease whose post-treatment sequelae are not well understood. For this study, we enrolled 152 individuals with symptoms of post-treatment LD (PTLD) to profile their peripheral blood mononuclear cells (PBMCs) with RNA sequencing (RNA-seq). Combined with RNA-seq data from 72 individuals with acute LD and 44 uninfected controls, we investigated differences in differential gene expression.

View Article and Find Full Text PDF

A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease.

PLoS One

October 2022

Division of Rheumatology, Department of Medicine, Lyme Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.

Article Synopsis
  • * In a study comparing 12 PTLD patients to 18 healthy controls using functional MRI (fMRI) and diffusion tensor imaging (DTI), PTLD patients showed slower response times on working memory tasks, and exhibited altered brain activation patterns, particularly in white matter areas of the frontal lobe.
  • * The findings suggest that changes in white matter integrity, indicated by higher axial diffusivity, may relate to cognitive functioning and longer illness duration, pointing to a potential healing process rather than ongoing damage in the brains
View Article and Find Full Text PDF
Article Synopsis
  • * The study utilized advanced RNA sequencing and machine learning to analyze gene expression in blood samples from various groups, including early Lyme patients, controls, and patients with other infections, leading to the identification of key genetic markers.
  • * A 31-gene classifier was developed that effectively distinguishes early Lyme disease patients from controls, achieving high sensitivity (90%), specificity (100%), and accuracy (95.2%), indicating its potential as a reliable diagnostic tool, even in seronegative patients.
View Article and Find Full Text PDF

Background: Peptidylarginine deiminase 2 (PAD2) mediates the post-translational conversion of arginine residues in proteins to citrullines and is highly expressed in the central nervous system (CNS). Dysregulated PAD2 activity has been implicated in the pathogenesis of several neurologic diseases, including multiple sclerosis (MS). In this study, we sought to define the cellular and regional expression of the gene encoding for PAD2 (i.

View Article and Find Full Text PDF

Disseminated Lyme disease and dilated cardiomyopathy: A systematic review.

Trends Cardiovasc Med

November 2023

Department of Medicine, Kingston Health Science Centre, Queen's University, Kingston General Hospital K7L 2V7, Kingston, ON, Canada. Electronic address:

Lyme carditis is a well-established manifestation of early disseminated Lyme infection, yet the relationship between late disseminated Lyme disease and the development of dilated cardiomyopathy (DCM) remains unclear. The present systematic review aims to summarize existing literature on the association between late disseminated Lyme disease and DCM. A systematic review was conducted in PubMed, Embase, CENTRAL, and MEDLINE databases, after which a total of 11 observational studies (n = 771) were ultimately included for final data extraction.

View Article and Find Full Text PDF

Purpose: Post-treatment Lyme disease (PTLD) is characterized by patient-reported symptoms after treatment for Borrelia burgdorferi infection. The primary aim of this study was to assess whether participants with a history of Lyme disease (LD) would be more likely to meet criteria for PTLD than those without a history of LD.

Methods: We conducted a longitudinal, prospective study among 234 participants with and 49 participants without prior LD.

View Article and Find Full Text PDF
Article Synopsis
  • Ixekizumab is a monoclonal antibody used for treating psoriasis and psoriatic arthritis (PsA), with the review focusing on its safety, efficacy from clinical trials, and the characteristics of study participants.
  • The analysis covered 13 studies, showing that injection site reactions (ISR) occurred more frequently with ixekizumab than placebo or adalimumab, but it had fewer serious adverse events compared to adalimumab.
  • Ixekizumab was found to be equally effective as adalimumab for PsA symptoms and even better for psoriasis outcomes, but the participant population was predominantly white and had high disease activity levels.
View Article and Find Full Text PDF

With the incidence of Lyme and other tickborne diseases on the rise in the US and globally, there is a critical need for data-driven tools that communicate the magnitude of this problem and help guide public health responses. We present the Johns Hopkins Lyme and Tickborne Disease Dashboard (https://www.hopkinslymetracker.

View Article and Find Full Text PDF

Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease in the United States with an estimated 476,000 cases per year. While historically, the long-term impact of Lyme disease on patients has been controversial, mounting evidence supports the idea that a substantial number of patients experience persistent symptoms following treatment. The research community has largely lacked the necessary funding to properly advance the scientific and clinical understanding of the disease, or to develop and evaluate innovative approaches for prevention, diagnosis, and treatment.

View Article and Find Full Text PDF

Evolving distal signs.

Cleve Clin J Med

June 2021

Thayer Firm, Osler Medical Service, Johns Hopkins Hospital; Professor of Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

View Article and Find Full Text PDF

Purpose: Posttreatment Lyme disease (PTLD) is marked by neurologic symptoms, cognitive impairment, and significant symptom burden, including fatigue and ocular complaints. The purpose of this study was to determine whether contrast sensitivity (CS) is altered in patients with PTLD compared with healthy controls and, second, whether CS is associated with cognitive and/or neurologic deficits.

Methods: CS was measured using a Pelli-Robson chart with forced-choice procedures, and the total number of letters read was recorded for each eye.

View Article and Find Full Text PDF

Although widely prevalent, Lyme disease is still under-diagnosed and misunderstood. Here we followed 73 acute Lyme disease patients and uninfected controls over a period of a year. At each visit, RNA-sequencing was applied to profile patients' peripheral blood mononuclear cells in addition to extensive clinical phenotyping.

View Article and Find Full Text PDF

Purpose: The erythema migrans (EM) skin lesion is often the first clinical sign of Lyme disease. Significant variability in EM presenting characteristics such as shape, color, pattern, and homogeneity, has been reported. We studied associations between these presenting characteristics, as well as whether they were associated with age, sex, EM duration, body location, and initiation of antibiotics.

View Article and Find Full Text PDF

Lyme Disease in the Era of COVID-19: A Delayed Diagnosis and Risk for Complications.

Case Rep Infect Dis

February 2021

Lyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

We describe a patient with fever and myalgia who did not have COVID-19 but instead had Lyme disease. We propose that the co-occurrence of COVID-19 and Lyme disease during the spring of 2020 resulted in a delayed diagnosis of Lyme disease due to COVID-19 pandemic-related changes in healthcare workflow and diagnostic reasoning. This delayed diagnosis of Lyme disease in the patient we describe resulted in disseminated infection and sixth nerve palsy.

View Article and Find Full Text PDF